Skip to main content
. 2016 Aug 31;7(51):84142–84154. doi: 10.18632/oncotarget.11776

Figure 5. DRS predicts response to taxane-anthracycline chemotherapy.

Figure 5

(A) Kaplan-Meier survival curves of taxane-anthracycline chemotherapy-treated breast cancer patients with DRSLY-294002 greater and less than 0. Each vertical line represents a censored patient. (B) Receiver Operating Characteristic (ROC) curve for random forest classification predicting residual cancer burden using DRSLY-294002. Random forest classification was conducted using (1) all breast tumors, (2) ER+ breast tumors only, and (3) ER– breast tumors only.